StockUS listing USHALONASDAQHealthcareQuality Compounder

Halozyme Therapeutics Inc(HALO) Stock Analysis | Healthcare

USD --+0.00%
Reward78High
Risk38Moderate
75%Data
Strong 25% profit margin · Revenue growing 48% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 12.53Bn
Reward Ratingⓘ78 High reward assessment · 75% data coverage
Top 10% of stocksView factors
Risk Ratingⓘ38 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HALO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Halozyme Therapeutics Inc?

, a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

AI Brief Pro

The brief on Halozyme Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Halozyme Therapeutics Inc?

, a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 12.53B, and a P/E ratio of 32.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (78)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio32.2866
Beta0.877
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
8118,857 shares
$8.3M
0
9-12months
645,661 shares
$3.1M
0